# SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases

Source: https://onco.cc/trials/nct06850103/  
OnCo record `nct06850103` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of serplulimab in colorectal cancer, run by First Affiliated Hospital of Zhejiang University, now recruiting.

## Summary

SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases is a phase 2, interventional study registered as NCT06850103 by First Affiliated Hospital of Zhejiang University, with a registry enrolment figure of 51 participants, started 2025-04-22 and due to reach its primary completion in 2027-12-31. Interventions recorded: short-course radiotherapy; CAPEOX/XELOX; Serplulimab; surgery. Conditions listed: Colorectal Carcinoma; Oligometastases; pMMR; MSS; iTNT. Primary outcome: 3-year PFS. Colorectal eligibility wording from the registry: "Histologically confirmed primary rectal adenocarcinoma, with MRI showing tumor location within 10cm from the anal verge". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06850103
- Phase: 2
- Setting: A Phase II Exploratory Multicenter Randomized Controlled Clinical Trial to Evaluate the Effectiveness of Neoadjuvant Short-Course Radiotherapy (SCRT) Followed by CAPEOX Chemotherapy and Serplulimab in Microsatellite Stable (MSS) or Proficient Mismatch Repair (pMMR) Rectal Cancer With Synchronous Oligometastases
- Sponsor: First Affiliated Hospital of Zhejiang University
- Enrolled: 51

## Sources

- ClinicalTrials.gov NCT06850103: https://clinicaltrials.gov/study/NCT06850103

## Connected records

- cancers: [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- drugs: [Serplulimab](https://onco.cc/drugs/serplulimab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06850103.json